Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 5Thoracic 3Other solid neoplasm 3Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Breast 2Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
WW Domain-Containing Oxidoreductase × Breast × Clear all
NCT07394946 2026-02-20

NELOPHER

Cancer Care Hospital & Research Centre Foundation, Lahore

Phase 2 Not yet recruiting
126 enrolled
Breast

Breast Neoplasms

NCT00083993 2011-11-08

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Terminated
1,236 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡